Search

Your search keyword '"Kopylov, Uri"' showing total 15 results
Start Over Author "Kopylov, Uri" Search Limiters Academic (Peer-Reviewed) Journals Journal journal of clinical medicine
15 results on '"Kopylov, Uri"'

1. Biologic Treatment Modification Efficacy in Concurrent Inflammatory Bowel Disease and Ankylosing Spondylitis: A Retrospective Cohort Study at a Single Tertiary Center

Author

Savin, Einat, primary, Ben-Shabat, Niv, additional, Levartovsky, Asaf, additional, Lahat, Adi, additional, Omar, Mahmud, additional, Gendelman, Omer, additional, Lidar, Merav, additional, Watad, Abdulla, additional, Ben-Horin, Shomron, additional, Kopylov, Uri, additional, and Sharif, Kassem, additional

Published
2023
Full Text
View/download PDF

3. Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Author

Albshesh, Ahmad, primary, Bannon, Lian, additional, Sharar Fischler, Tali, additional, Truyens, Marie, additional, Vavricka, Stephan R., additional, Tepes, Katja, additional, Pugliese, Daniela, additional, Savarino, Edoardo V., additional, Zittan, Eran, additional, Drobne, David, additional, Roblin, Xavier, additional, Bar-Gil Shitrit, Ariella, additional, Armuzzi, Alessandro, additional, Lobaton, Triana, additional, Maharshak, Nitsan, additional, Yanai, Henit, additional, Ben-Horin, Shomron, additional, and Kopylov, Uri, additional

Published
2023
Full Text
View/download PDF

4. A Novel Prediction Tool for Endoscopic Intervention in Patients with Acute Upper Gastro-Intestinal Bleeding

Author

Veisman, Ido, primary, Oppenheim, Amit, additional, Maman, Ronny, additional, Kofman, Nadav, additional, Edri, Ilan, additional, Dar, Lior, additional, Klang, Eyal, additional, Sina, Sigal, additional, Gabriely, Daniel, additional, Levy, Idan, additional, Beylin, Dmitry, additional, Beylin, Ortal, additional, Shekel, Efrat, additional, Horesh, Nir, additional, and Kopylov, Uri, additional

Published
2022
Full Text
View/download PDF

9. Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Author

Albshesh, Ahmad, primary, Taylor, Joshua, additional, Savarino, Edoardo V., additional, Truyens, Marie, additional, Armuzzi, Alessandro, additional, Ribaldone, Davide G., additional, Shitrit, Ariella Bar-Gil, additional, Fibelman, Morine, additional, Molander, Pauliina, additional, Liefferinckx, Claire, additional, Nancey, Stephane, additional, Korani, Mohamed, additional, Rutka, Mariann, additional, Barreiro-de Acosta, Manuel, additional, Domislovic, Viktor, additional, Suris, Gerard, additional, Eriksson, Carl, additional, Alves, Catarina, additional, Mpitouli, Afroditi, additional, di Jiang, Caroline, additional, Tepeš, Katja, additional, Coletta, Marina, additional, Foteinogiannopoulou, Kalliopi, additional, Gisbert, Javier P., additional, Amir-Barak, Hadar, additional, Attauabi, Mohamed, additional, Seidelin, Jakob, additional, Afif, Waqqas, additional, Marinelli, Carla, additional, Lobaton, Triana, additional, Pugliese, Daniela, additional, Maharshak, Nitsan, additional, Cremer, Anneline, additional, Limdi, Jimmy K., additional, Molnár, Tamás, additional, Otero-Alvarin, Borja, additional, Krznaric, Zeljko, additional, Magro, Fernando, additional, Karmiris, Konstantinos, additional, Raine, Tim, additional, Drobne, David, additional, Koutroubakis, Ioannis, additional, Chaparro, Maria, additional, Yanai, Henit, additional, Burisch, Johan, additional, and Kopylov, Uri, additional

Published
2021
Full Text
View/download PDF

11. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Author

Allocca, Mariangela, primary, Chaparro, María, additional, Gonzalez, Haidee Aleman, additional, Bosca-Watts, Marta Maia, additional, Palmela, Carolina, additional, D’Amico, Ferdinando, additional, Zacharopoulou, Eirini, additional, Kopylov, Uri, additional, Ellul, Pierre, additional, Bamias, Giorgos, additional, Ntelis, Vassilios, additional, Lahat, Adi, additional, Mantzaris, Gerassimos J, additional, Papaconstantinou, Ioannis, additional, Katsanos, Konstantinos, additional, Uspenskaya, Yulia, additional, Christodoulou, Dimitrios, additional, Ben Horin, Shomron, additional, Peyrin-Biroulet, Laurent, additional, Torres, Joanna, additional, Sebastian, Shaji, additional, Gisbert, Javier P, additional, Danese, Silvio, additional, and Fiorino, Gionata, additional

Published
2020
Full Text
View/download PDF

14. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis.

Author

Guberna, Laura, Nyssen, Olga P., Chaparro, María, Gisbert, Javier P., and Kopylov, Uri

Subjects
INFLAMMATORY bowel diseases, CROHN'S disease, ULCERATIVE colitis, DRUG monitoring, RANDOM effects model
Abstract

Loss of response to antitumor necrosis factor (anti-TNF) therapies in inflammatory bowel disease occurs in a high proportion of patients. Our aim was to evaluate the loss of response to anti-TNF therapy, considered as the need for dose intensification (DI), DI effectiveness and the possible variables influencing its requirements. Bibliographical searches were performed. Selection: prospective and retrospective studies assessing DI in Crohn's disease and ulcerative colitis patients treated for at least 12 weeks with an anti-TNF drug. Exclusion criteria: studies using anti-TNF as a prophylaxis for the postoperative recurrence in Crohn's disease or those where DI was based on therapeutic drug monitoring. Data synthesis: effectiveness by intention-to-treat (random effects model). Data were stratified by medical condition (ulcerative colitis vs. Crohn's disease), anti-TNF drug and follow-up. Results: One hundred and seventy-three studies (33,241 patients) were included. Overall rate of the DI requirement after 12 months was 28% (95% CI 24–32, I2 = 96%, 41 studies) in naïve patients and 39% (95% CI 31–47, I2 = 86%, 18 studies) in non-naïve patients. The DI requirement rate was higher both in those with prior anti-TNF exposure (p = 0.01) and with ulcerative colitis (p = 0.02). The DI requirement rate in naïve patients after 36 months was 35% (95% CI 28–43%; I2 = 98%; 18 studies). The overall short-term response and remission rates of empirical DI in naïve patients were 63% (95% CI 48–78%; I2 = 99%; 32 studies) and 48% (95% CI: 39–58%; I2 = 92%; 25 studies), respectively. The loss of response to anti-TNF agents―and, consequently, DI―occurred frequently in inflammatory bowel disease (approximately in one-fourth at one year and in one-third at 3 years). Empirical DI was a relatively effective therapeutic option. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. Thiopurines’ Metabolites and Drug Toxicity: A Meta-Analysis

Author

Paula Sousa, Fernando Magro, Paula Ministro, Maria Manuela Estevinho, Cláudia Camila Dias, Laurent Peyrin-Biroulet, Silvio Danese, Uri Kopylov, Sousa, Paula, Estevinho, Maria Manuela, Dias, Cláudia Camila, Ministro, Paula, Kopylov, Uri, Danese, Silvio, Peyrin-Biroulet, Laurent, and Magro, Fernando

Subjects
Leukopenia, medicine.diagnostic_test, thiopurines, business.industry, therapeutic drug monitoring, lcsh:R, lcsh:Medicine, Review, General Medicine, Odds ratio, Pharmacology, adverse events, 03 medical and health sciences, 0302 clinical medicine, Therapeutic drug monitoring, 030220 oncology & carcinogenesis, Meta-analysis, Toxicity, Medicine, 030211 gastroenterology & hepatology, In patient, medicine.symptom, business, Adverse effect, Drug toxicity
Abstract

Many questions remain unanswered regarding therapeutic drug monitoring (TDM) utility with thiopurines. This study aims to establish a relationship between thiopurines’ metabolites and drug toxicity. We performed a systematic review with inclusion of studies evaluating the relationship between thiopurines’ metabolites and drug toxicity. Meta-analysis of mean difference (MD), correlations and odds ratio (OR) was performed. We identified 21,240 records, 72 of which were eligible for meta-analysis. Levels of 6-thioguanine nucleotides (6-TGN) were higher in patients with leukopenia (MD 127.06 pmol/8 × 108 RBC) and gastrointestinal intolerance (MD 201.46 pmol/8 × 108 RBC), and lower in patients with hepatotoxicity (MD −40.6 pmol × 108 RBC). We established a significant correlation between 6-TGN and leukocytes (r = −0.21), neutrophils (r = −0.24) and alanine aminotransferase levels (r = −0.24). OR for leukopenia in patients with elevated 6-TGN was 4.63 (95%CI 2.24; 9.57). An optimal cut-off of 135 pmol/8 × 108 RBC for leukopenia was calculated (sensitivity 75.4%; specificity 46.4%). 6-methylmercaptopurine ribonucleotides (6-MMPR) were significantly associated with hepatotoxicity (MD 3241.2 pmol/8 × 108 RBC; OR 4.28; 95%CI 3.20; 5.71). Levels of 6-MMPR measured in the first 8 weeks of treatment were associated with leukopenia. We conclude that TDM could be used to prevent thiopurines’ toxicity. As optimal metabolites level may vary according to indication, physicians may adapt posology to decrease toxicity without compromising efficacy.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results